» Articles » PMID: 33256657

The Age Threshold of the 8th Edition AJCC Classification is Useful for Indicating Patients with Aggressive Papillary Thyroid Cancer in Clinical Practice

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2020 Dec 1
PMID 33256657
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Papillary thyroid cancer (PTC) is unique among cancers in that patient age is a consideration in staging. One of the most important modifications in the 8th Edition of the American Joint Committee on Cancer (AJCC) classification is to increase the age cut off for risk stratification in PTC from 45 to 55 years. However, whether this cut off is useful in clinical practice remains controversial. In the present study, we assessed how well this new age threshold stratifies patients with aggressive PTC.

Methods: We retrospectively analyzed the clinicopathological features and overall survival rate of patients with PTC admitted to and surgically treated at a single surgical center. The study protocol was divided into two series. In each series all patients (n = 523) were divided in 2 groups according to age cut off. In the first series (cut off 45) patients < 45 (n = 193) vs. ≥45 (n = 330) were compared, and in the second series (cut off 55) patients < 55 (n = 306) vs. ≥55 (n = 217) were compared.

Results: The rate of the prevalence of locally advanced disease (pT3 and pT4) was significantly higher in the patients above 55 years old than in those below 55 years old (p = 0.013). No significant differences were found for this parameter in series with cut off point 45 years old. A significantly higher risk of locally advanced disease T3 + T4 (OR = 4.87) and presence of LNM (N1) (OR = 3.78) was observed in ≥45 years old group (p = 0.021 and p < 0.0001, respectively). More expressive results were found for the patients ≥55 years old group, where the risk of locally advanced disease (T3 + T4) was higher (OR = 5.21) and LNM presence was OR = 4.76 (p < 0.001 and p < 0.0001, respectively). None of the patients below 55 years old showed distant metastasis, but 19 patients above 55 years old showed M1 (p < 0.0001). In older patients group (≥55 years old) we observed deaths related thyroid cancer in 11 individuals.

Conclusions: The age cut off of 55 years old for risk stratification proposed by the 8th Edition of AJCC effectively stratifies PTC patients with a poor prognosis, indicating it is likely to be useful in clinical practice.

Citing Articles

A Machine Learning-Based Model for Preoperative Assessment and Malignancy Prediction in Patients with Atypia of Undetermined Significance Thyroid Nodules.

Moon G, Park J, Lee T, Yoon J J Clin Med. 2025; 13(24.

PMID: 39768693 PMC: 11727776. DOI: 10.3390/jcm13247769.


Effects of fibroblast growth factor 21 serum level on clinicopathological findings in papillary thyroid carcinoma.

Mosalamiaghili S, Akbari H, Lashkarbolouk N, Ariannia A, Mehrjerdian M, Salamat F Caspian J Intern Med. 2024; 16(1):58-65.

PMID: 39619743 PMC: 11607124. DOI: 10.22088/cjim.16.1.58.


High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks.

Zhang J, Xu S Cell Death Discov. 2024; 10(1):378.

PMID: 39187514 PMC: 11347646. DOI: 10.1038/s41420-024-02157-2.


Lymph Node Metastasis in Papillary Thyroid Carcinoma, A Study of BRAF V600E and TERT Promoter Mutations.

Soeratman A, Kartini D, Andinata B, Harahap A, Sudarsono N Asian Pac J Cancer Prev. 2024; 25(6):2043-2049.

PMID: 38918666 PMC: 11382857. DOI: 10.31557/APJCP.2024.25.6.2043.


Temporal trends of thyroid cancer between 2010 and 2019 in Asian countries by geographical region and SDI, comparison with global data.

Rezaei F, Mazidimoradi A, Pasokh Z, Dehghani S, Allahqoli L, Salehiniya H Aging Med (Milton). 2024; 6(4):386-426.

PMID: 38239716 PMC: 10792336. DOI: 10.1002/agm2.12277.


References
1.
Jeon M, Kim W, Kim T, Kim H, Kim B, Yi H . Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study. Endocrinol Metab (Seoul). 2017; 32(4):434-441. PMC: 5744729. DOI: 10.3803/EnM.2017.32.4.434. View

2.
de Castro T, Waissmann W, Simoes T, de Mello R, Carvalho D . Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study. Clin Endocrinol (Oxf). 2016; 85(3):466-74. DOI: 10.1111/cen.13032. View

3.
Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M, Dal Maso L . Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016; 375(7):614-7. DOI: 10.1056/NEJMp1604412. View

4.
Zambeli-Ljepovic A, Wang F, Dinan M, Hyslop T, Roman S, Sosa J . Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage. J Surg Res. 2019; 243:189-197. PMC: 6773493. DOI: 10.1016/j.jss.2019.05.029. View

5.
Yan H, Winchester D, Prinz R, Wang C, Nakazato Y, Moo-Young T . Differences in the Impact of Age on Mortality in Well-Differentiated Thyroid Cancer. Ann Surg Oncol. 2018; 25(11):3193-3199. DOI: 10.1245/s10434-018-6668-2. View